2bind’s Target Feasibility Platform: A Standardized Biophysical Assessment of Protein Target Suitability for Small Molecule and Peptide Binding Assays
July 2026, Regensburg, Germany – 2bind GmbH, a leading contract research organization (CRO) serving the global drug discovery and development sector, now offers a standardized Target Feasibility Platform that allows for a methodologically robust, biophysical evaluation of a protein target’s suitability for relevant binding assays.
Launch of Commercial Unit: 2bind Formalizes a Dedicated Commercial Structure
March 2026, Regensburg, Germany – 2bind GmbH, a leading CRO serving the global drug discovery and development sector, today announced the formal establishment of a dedicated commercial unit.
2bind Hosts Keynote & Roundtable Discussion by Till Maurer
June 2026, Regensburg, Germany – 2bind GmbH recently had the pleasure of hosting Till Maurer, a drug discovery expert with extensive industry experience and founder of Nanomol Pharmaceutical Innovations (NPI), for an internal expert talk on small molecule drug discovery.
2bind as a Corporate Sponsor of the PEGS Boston 2026 to Underline its Motivation in the Antibody Industry
May 2026, Regensburg, Germany – 2bind GmbH, a leading contract research organization (CRO) serving the global drug discovery and development sector, was for the first time a corporate sponsor of PEGS Boston 2026, one of the most prominent conferences in the field of protein and antibody engineering.
2bind Obtains ISO 9001:2015 Certification for Its Quality Management System
2bind GmbH, a leading contract research organization serving the global drug discovery and development sector, today announced that its Quality Management System has been officially certified to the ISO 9001:2015 standard.
2bind Expands Cell-Based Capabilities with New BSL2 Certified Laboratory
2bind GmbH, a leading CRO serving the global drug discovery and development sector, today announced the official commissioning of its newly established BSL2 cell culture laboratory.
2bind Launches Redesigned Website Aligned with Its “Pharma Services” Core Positioning
March 2026, Regensburg, Germany – 2bind GmbH, a leading contract research organization (CRO) serving the global drug discovery and development sector, today announced the official launch of its newly redesigned corporate website. Following the recent transition of its corporate identity from “Experts in Biophysics” to “Pharma Services,” this digital overhaul ensures that 2bind’s online presence fully reflects its expanded portfolio, modern assay ecosystem, and deep alignment with the biopharma market.
Evolution of a Trusted Partner: 2bind Transitions Corporate Identity from “Experts in Biophysics” to “Pharma Services”
2bind GmbH, a leading contract research organization (CRO) serving the global drug discovery and development sector, today announced a strategic evolution of its corporate identity. Reflecting its expanded portfolio and deep alignment with the life sciences industry, the company is transitioning its core positioning from “Experts in Biophysics” to “Pharma Services.”
scIC Delivers Best-in-Class, Real-time Kinetics on Cells
Single-cell interaction cytometry (scIC) is a cell-based method for measuring binding kinetics directly on intact living or fixed cells under near-physiological conditions. It delivers real-time kinetic parameters — kon, koff, KD, and avidity — without requiring target purification or surface immobilization. The approach preserves the native membrane environment throughout the measurement, making it relevant for a wide range of targets that are difficult or impossible to study with conventional biophysical platforms.
Launch of Antibody Unit with Dr. Vera Molkenthin as Director
2bind GmbH Launches Antibody Unit with Appointment of Dr. Vera Molkenthin as Director